Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, announce that the AACR has published online the company’s abstract for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. As described in the abstract, investigators will present first evidence that A2B receptor inhibition reduces the adenosine-mediated increase in PD-L1 in a hu ...